메뉴 건너 뛰기
SinilPharm

R&D Pipeline

Sinil Pharmaceutical Co., Ltd’s Life Science R&D Center

SINIL’s Life Science R&D Center has developed general, professional, bio, and natural drugs by carrying out effective R&D through core technology development, effective joint research with other exterior institutions, and close cooperation with relevant divisions. The Life Science R&D Center can boast of global competiveness in R&D by applying for patents at home and abroad and publishing academic studies.


Category Name Indication Development Stage
INDICATION RESEARCH PRE-CLINCAL PHASE I PHASE II PHASE III
Natural drug SI 000413

Osteoarthritis

 
SI 000902 Rheumatoid Arthritis
 
SI N1501 Obesity
 
SI N1502 Dementia
 
Modified New Drugs SI 000513 Osteoporosis
 
Bio Better SI600265 Bio Better
 
SI800265 Breast Cancer
 

Sinil Pharmaceutical Co., Ltd’s Life Science R&D Center

SINIL’s Life Science R&D Center has focused on R&D to improve chronic and incurable diseases as well as quality of life, which has high demand in the market, by carrying out national projects with partners, such as domestic public institutions and colleges.


Research Subject Period Role ministry Remark
Patent strategy consulting - technology valuation of natural product for anti-arthritis and survey of partnering companies 2016.08 ~ 2016.11 Supervision Ministry of Trade, Industry and Energy Underway
Commercialization of anti-wrinkle functional cosmetic materials [wheat extract] 2016.07 ~ 2016.11 Supervision Small and medium Business Corporation Underway
RA consulting of a breast cancer dignositics Kits 2016.07 ~ 2016.12 Part Korea Research Institute of Bioscience and Biotechnology Underway
Efficacy evaluation of site-specific drug conjugates 2016.07 ~ 2016.12 Part Korea Research Institute of Bioscience and Biotechnology Underway
Development of a new bio-drug candidates using antibody drug conjugational techniques 2016.05 ~ 2017.04 Part Small and Medium Business Administration Underway
Development of DPP-4 inhibitor generic medicine as a diabetes inhibitor 2015.12 ~ 2016.01 Supervision Chungbuk Technopark Completed
Efficacy evaluation of EGFR binding specific Fab fragment 2015.10 ~ 2016.02 Part Chungbuk Technopark Completed
Efficacy evaluation of antibody fragment drug conjugates in in-vivo and in-vitro 2015.10 ~ 2016.02 Part Korea Research Institute of Bioscience and Biotechnology Completed
Development of anti-cancer therapeutic lead material using a humanizated antibody fragments 2015.09 ~ 2016.08 Part Small and Medium Business Administration Completed
Development of breast cancer diagnostics of novel biomarker for early detection of breast cancer 2015.05 ~ 2018.04 Supervision Ministry of Trade, Industry and Energy Underway
Development of Functional Cosmetic Materials with wheat extract and commercialization 2013.09 ~ 2015.08 Supervision Ministry of Trade, Industry and Energy Completed
Development of EGFR-targeted bio-better antibodies as anti-cancer drug 2012.05 ~ 2015.04 Supervision Ministry of Knowledge Economy Completed
Vitamin composite to prevent metabolic diseases applying DDS technology 2011.04 ~ 2013.03 Supervision Ministry of Knowledge Economy Completed
Development of rheumatoid disease drug using natural products 2008.12 ~ 2011.09 Supervision Ministry of Knowledge Economy Completed
Development of nano DDS medicine for osteo-joint disease 2007.07 ~ 2009.06 Supervision Ministry of Trade, Industry and Energy Completed
Development of DNA aptamer as an effective anti-inflammation substance against avian influenza virus 2006.04 ~ 2009.04 Supervision Ministry of Agriculture, Food and Rural Affairs Completed
Development of agents for intractable diseases using natural products 2004.12 ~ 2006.09 Supervision Ministry of Trade, Industry and Energy Completed
Development of agents for degenerative inflammatory disease using natural products and commercialization 2004.12 ~ 2006.09 Supervision Ministry of Trade, Industry and Energy Completed